CpG ODN 1826 enhances radiosensitivity of the human lung cancer cell line A549 in a rat model.
This study investigated the effects of CpG ODN1826 plus radiotherapy (RT) on tumor growth and angiogenesis of subcutaneous tumor in a rat model. Four treatment groups were tested in which rats were injected with 100 μL CpG ODN1826 (1 μg/μL) or 100 μL vehicle, with and without exposure to 8 Gy after 2 h. At 7 days after inoculation of lung cancer cells, drugs were injected in the tumor and radiation was administered over 5 days, after which the rate of tumor inhibition was calculated. Expression of VEGF-C in tumor tissue was seen in 10, 50, 80, and 100% of tumors in the CpG ODN1826 + RT, CpG ODN1826, vehicle + RT, and vehicle alone groups, respectively, while positive expression of NRP-1 was seen in 10, 40, 90, and 100% of tumors. The decreases in expression of VEGF-C mRNA in the CpG ODN1826 + RT and CpG ODN1826 groups compared with the NS + RT and NS groups were significant (P < 0.01), as were the decreases in NRP-1 mRNA in the CpG ODN1826 + RT group compared with the CpG ODN1826 group (P < 0.01). Thus, CpG ODN1826 can significantly inhibit tumor growth in a rat model, the mechanism of which may be related to inhibition of the expression of VEGF-C and NRP-1, which have an inhibitory effect on angiogenesis.
The Cadre Ward of Air Force General Hospital, Beijing, China.
W
W
Yan
The Cadre Ward of Air Force General Hospital, Beijing, China suntiye_sty@163.com.
T-Y
TY
Sun
The Cadre Ward of Air Force General Hospital, Beijing, China.
C-M
CM
Yang
The Cadre Ward of Air Force General Hospital, Beijing, China.
M
M
Jia
The Cadre Ward of Air Force General Hospital, Beijing, China.
J
J
Li
The Cadre Ward of Air Force General Hospital, Beijing, China.
H-L
HL
Tang
The Cadre Ward of Air Force General Hospital, Beijing, China.
Y-F
YF
Zhou
D000818:Animals; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D015870:Gene Expression; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy; D039942:Neuropilin-1 / Q000235:genetics; D009838:Oligodeoxyribonucleotides / Q000008:administration & dosage / Q000494:pharmacology*; D012333:RNA, Messenger / Q000235:genetics; D011836:Radiation Tolerance / Q000187:drug effects*; D051381:Rats; D047368:Tumor Burden / Q000187:drug effects / Q000528:radiation effects; D042582:Vascular Endothelial Growth Factor C / Q000235:genetics; D023041:Xenograft Model Antitumor Assays
C423449:CpG ODN 1826; D009838:Oligodeoxyribonucleotides; D012333:RNA, Messenger; D042582:Vascular Endothelial Growth Factor C; D039942:Neuropilin-1